Lexaria Bioscience Corp
For the period ended Aug 31, 2024. Filed Nov 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Nov 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
| By: | /s/ Richard Christopher |
|---|
In accordance with the Exchange Act, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| By: | /s/ Richard Christopher |
|---|
| By: | /s/ Michael Shankman |
|---|
| By: | /s/ William Edward (Ted) McKechnie |
|---|
| By: | /s/ Nicholas Baxter |
|---|
| By: | /s/ Albert Reese Jr. |
|---|
| By: | /s/ Dr. Catherine C. Turkel |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.